## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.22 indicates fundamental undervaluation. Quality metrics strong (ROE 136%, ROA 12%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-3.9% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($478.08)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Johnson Financial Group Inc. Sells 1,831 Shares of HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251201T112251 | Bullish | Relevance: 99%
- Johnson Financial Group Inc. significantly reduced its stake in HCA Healthcare, Inc. by selling 1,831 shares, retaining only 230 shares worth approximately $88,000. Despite this sell-off, HCA Healthcare reported strong quarterly earnings, beating analyst estimates, which led to analysts raising their price targets and maintaining a "Moderate Buy" consensus. The article also highlights other institutional and insider trading activities, including increased holdings by some institutions and sales by executive VPs.

**2. Employees Retirement System of Texas Invests $590,000 in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251129T114421 | Bullish | Relevance: 99%
- The Employees Retirement System of Texas purchased a new stake of 1,540 shares in HCA Healthcare, Inc. worth approximately $590,000 during the second quarter. HCA Healthcare reported strong earnings, exceeding analyst estimates, and received a "Moderate Buy" consensus rating with an average target price of $474.53 from Wall Street analysts. Despite some insider selling, institutional investors hold a significant portion of the company's stock.

**3. HCA Healthcare, Inc. $HCA Shares Sold by New York State Common Retirement Fund**
- Source: MarketBeat | 20251201T115105 | Neutral | Relevance: 99%
- The New York State Common Retirement Fund decreased its stake in HCA Healthcare by 5.5% in Q2, selling 18,346 shares and now owning 316,402 shares valued at $121.2 million. Despite this, HCA Healthcare reported strong quarterly earnings, beating analyst expectations with $6.96 EPS and $19.16 billion in revenue, and issued optimistic FY2025 guidance. Analysts maintain a "Moderate Buy" rating with a consensus price target of $474.53, while the company announced a quarterly dividend of $0.72 per share.

**4. HCA Healthcare (HCA) Stock on December 1, 2025: Near Allâ€‘Time Highs, Upgraded Guidance and What Comes Next**
- Source: ts2.tech | 20251201T225926 | Bullish | Relevance: 99%
- HCA Healthcare (HCA) stock approached all-time highs on December 1, 2025, driven by upgraded guidance, strong institutional interest, and robust financial performance. Third-quarter 2025 results exceeded expectations, leading to an increased full-year EPS forecast of $27-28 per share. Despite the significant rally, HCA's valuation remains at a discount to the broader market on key cash-flow metrics, even as analyst price targets lag the current stock price.

**5. F m Investments LLC Invests $4.08 Million in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251130T100618 | Bullish | Relevance: 98%
- F m Investments LLC initiated a new position in HCA Healthcare Inc. (NYSE:HCA) during the second quarter, acquiring 10,657 shares valued at approximately $4.08 million. This investment follows a period where HCA Healthcare exceeded Q3 earnings expectations, reporting $6.96 EPS against a $5.64 consensus and $19.16 billion in revenue, prompting a positive outlook with FY2025 guidance set at $27.00-$28.00 EPS. Despite some insider selling, the company has declared a quarterly dividend of $0.72 per share, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $474.53.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | Wells Fargo | $431 | $412 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Heavy insider selling: $15M sold (4 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.22 suggests fair value with growth premium. Forward P/E 16.9x stretched relative to 8% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $109.7B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.22 |
| Forward P/E | 16.9 |
| Current P/E | 18.2 |
| YoY Growth | 7.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 7.1% to 3.2% (-3.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.8pp (needs >4.0% for momentum thesis). MRS_5 (-1.6%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 4.3% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.75), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.21% (CS: 80) | Neutral |
| RSI_14 | 67.0 | Neutral |
| MACD Histogram | 1.75 | Bullish |
| vs SMA20 | 1.043x | Above |
| vs SMA50 | 1.113x | Above |
| vs SMA200 | 1.308x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $503.00
- **Stop Loss:** $478.08 (5.0% risk)
- **Target:** $552.84 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 30
- **Position Value:** $15,090.00
- **Portfolio %:** 15.09%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*